9 unknown, 8 recruiting, 6 completed, 3 not yet recruiting. 28 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 28 | Unknown 9, Recruiting 8, Completed 6, Not yet recruiting 3, Active not recruiting 1, Terminated 1 |
Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 4 | Recruiting | The First Hospital of Jilin University | 26 | 2026-10-15 | 2026-11-02 |
| Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 4 | Not yet recruiting | The First Hospital of Jilin University | 27 | 2026-09-01 | 2026-08-12 |
| Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 4 | Recruiting | Beijing Tongren Hospital | 88 | 2025-11-25 | 2026-01-21 |
| Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma Rituximab, Zanubrutinib - Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2025-11-01 | 2025-12-08 |
| Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL) chidamide+PD-1 inhibitor - Large B-Cell Lymphoma (LBCL), Lymphoma, Large B-Cell, Diffuse | Phase 4 | Recruiting | Shanghai Tongji Hospital, Tongji University School of Medicine | 20 | 2025-10-30 | 2026-11-16 |
| Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma Glofitamab treatment - B Cell Lymphoma (BCL) | Phase 4 | Not yet recruiting | Zhengzhou University | 40 | 2025-05-30 | 2025-05-02 |
| Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma Axicabtagene Ciloleucel - Lymphoma, B-Cell | Phase 4 | Recruiting | Zhengzhou University | 20 | 2024-09-30 | 2024-10-15 |
| A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma Relmacabtagene Autoleucel Injection - Relapsed or Refractory B-cell Lymphoma | Phase 4 | Not yet recruiting | Changhai Hospital | 13 | 2023-06-20 | 2023-06-15 |
| Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma Relma-cel - Relapsed or Refractory B-cell Lymphoma | Phase 4 | Recruiting | Ruijin Hospital | 8 | 2023-05-01 | 2024-10-23 |
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma selinexor - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 4 | Unknown | Chongqing University Cancer Hospital | 32 | 2023-02-28 | 2023-03-28 |
| Clinical Study of OR for Second-line Treatment of Refractory MZL Orelabrutinib combined with rituximab - OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma | Phase 4 | Recruiting | Lixia Sheng | 39 | 2023-01-02 | 2024-06-11 |
| B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine - Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma | Phase 4 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 300 | 2022-05-25 | 2022-08-26 |
| Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit - Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 4 | Completed | Vanderbilt-Ingram Cancer Center | 25 | 2021-12-02 | 2025-03-27 |
| R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL R2-combination chemotherapy, R-combination chemotherapy - Lymphoma, B-Cell | Phase 4 | Unknown | Shandong Provincial Hospital | 200 | 2019-06-05 | 2019-11-05 |
| A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Decitabine - Diffuse Large B Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 60 | 2018-06-01 | 2018-09-14 |
| Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma (R)-CHOP regimen, (R)-CVP regimen - Diffuse Large B Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 20 | 2017-07-01 | 2018-05-01 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Ibrutinib - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin | Phase 4 | Active not recruiting | Pharmacyclics Switzerland GmbH | 297 | 2017-05-22 | 2025-10-30 |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma Apatinib - Relapsed and Refractory, Diffuse Large B Cell Lymphoma | Phase 4 | Completed | Zhengzhou University | 32 | 2017-01-01 | 2019-07-25 |
| Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma IL-2 pre-treated CD19 cells, IL-7/IL-15 pre-treated CD19 cells - Lymphoma, B Cell | Phase 4 | Unknown | jiangjingting | 10 | 2016-12-01 | 2016-12-14 |
| PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia rhG-CSF regimen, Pegylated rhG-CSF regimen - Lymphoma,Non-Hodgkin | Phase 4 | Unknown | Shandong Provincial Hospital | 240 | 2016-11-01 | 2016-12-19 |
Showing 20 of 28. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (14) · Burkitt Lymphoma (5) · Recurrence (5) · Lymphoma, Non-Hodgkin (4) · Lymphoma, B-Cell, Marginal Zone (3) · Graft vs Host Disease (2) · Hodgkin Disease (2) · Lymphoma (2) · Lymphoma, T-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia (1) · Blast Crisis (1) · Dendritic Cell Sarcoma, Interdigitating (1) · HIV Infections (1)
Hemic and Lymphatic Diseases (28) · Immune System Diseases (27) · Immunoproliferative Disorders (27) · Lymphatic Diseases (27) · Lymphoproliferative Disorders (27) · Neoplasms (27) · Neoplasms by Histologic Type (27) · Lymphoma (26) · Lymphoma, Non-Hodgkin (24) · Infections (6) · Virus Diseases (6) · DNA Virus Infections (5) · Disease Attributes (5) · Epstein-Barr Virus Infections (5)
Rituximab (7) · Cyclophosphamide (6) · Doxorubicin (3) · Vincristine (3) · Cytarabine (2) · Dexamethasone (2) · Etoposide (2) · Ifosfamide (2) · Methotrexate (2) · Prednisone (2) · axicabtagene ciloleucel (2) · relmacabtagene autoleucel (2) · Antilymphocyte Serum (1) · Antiretroviral Therapy, Highly Active (1) · Blood Pressure (1)
Mingzhi Zhang (3) · Zhengzhou University (3) · Ruijin Hospital (2) · Shandong Provincial Hospital (2) · The First Hospital of Jilin University (2) · Beijing Tongren Hospital (1) · Changhai Hospital (1) · Chongqing University Cancer Hospital (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Lixia Sheng (1) · Millennium Pharmaceuticals, Inc. (1) · Nicola Goekbuget (1) · PETHEMA Foundation (1) · Pharmacyclics Switzerland GmbH (1) · Seoul National University Hospital (1)
China (17) · Spain (3) · United States (3) · Czechia (2) · France (2) · Germany (2) · Poland (2) · Russia (2) · South Korea (2) · Turkey (Türkiye) (2) · Australia (1) · Canada (1) · Hungary (1) · Italy (1) · Malaysia (1)
Barry R. Meisenberg, MD (1) · Jingting Jiang, Professor (1) · Kevin Wu (1) · Li Chen (1) · Liang Wang, MD (1) · Mingzhi Zhang (1) · Mingzhi Zhang, Dr (1) · Nicola Goekbuget, Dr. med. (1) · Olalekan Oluwole, MD (1) · Oriol Albert, Dr (1) · Ribera Josep M, Dr (1)
PMID 16648042, PMID 19219604, PMID 20660832, PMID 23615461, PMID 23753028, PMID 25359988, PMID 25934708, PMID 26808342, PMID 29155058, PMID 29437609, PMID 29610030, PMID 29654631, PMID 30881137, PMID 31733578, PMID 32158186, PMID 32487143, PMID 32589977, PMID 33002134, PMID 33148342, PMID 33202794, PMID 33764240, PMID 34222013, PMID 35240677, PMID 37173224, PMID 37403255, PMID 37463687, PMID 38578828, PMID 39272927, PMID 39853608, PMID 7477169
2016 (1)